- Amended Statement of Ownership (SC 13G/A)
October 10 2012 - 9:59AM
Edgar (US Regulatory)
|
|
|
|
UNITED STATES
|
|
|
SECURITIES AND EXCHANGE COMMISSION
|
|
|
Washington, D.C. 20549
|
|
|
SCHEDULE 13G
|
|
Under the Securities Exchange Act of 1934
|
(Amendment No. 2)*
|
|
Par Pharmaceutical Companies, Inc.
|
|
(Name
of Issuer)
|
|
Common Stock
|
|
(Title
of Class of Securities)
|
|
69888P106
|
|
(CUSIP
Number)
|
|
September 30, 2012
|
|
(Date
of Event Which Requires Filing of this Statement)
|
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
|
|
|
|
x
|
Rule 13d-1(b)
|
|
|
|
|
o
|
Rule 13d-1(c)
|
|
|
|
|
o
|
Rule 13d-1(d)
|
*The remainder of this cover
page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in
a prior cover page.
The information required in
the remainder of this cover page shall not be deemed to be filed for the
purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or
otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No. 69888P106
|
|
|
|
|
|
1.
|
Names of Reporting Persons
Lord, Abbett & Co. LLC
|
|
|
|
|
|
2.
|
Check the Appropriate Box
if a Member of a Group (See Instructions)
|
|
|
(a)
|
o
|
|
|
|
|
|
|
(b)
|
o
|
|
|
|
|
|
|
3.
|
SEC Use Only
|
|
|
|
|
|
4.
|
Citizenship or Place of
Organization
Delaware
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
711,279
|
|
|
|
6.
|
Shared Voting Power
0
|
|
|
|
7.
|
Sole Dispositive Power
774,279
|
|
|
|
8.
|
Shared Dispositive Power
0
|
|
|
|
|
|
9.
|
Aggregate Amount
Beneficially Owned by Each Reporting Person
774,279
|
|
|
|
|
|
10.
|
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)
o
N/A
|
|
|
|
|
|
11.
|
Percent of Class
Represented by Amount in Row (9)
2.10%
|
|
|
|
|
|
12.
|
Type of Reporting Person
(See Instructions)
IA
|
|
|
|
2
|
|
|
|
Item 1.
|
|
(a)
|
Name of Issuer
Par Pharmaceutical Companies, Inc.
|
|
|
|
|
(b)
|
Address of Issuers
Principal Executive Offices
300 Tice Boulevard
Woodcliff Lake, NJ 07677
|
|
|
|
|
Item 2.
|
|
(a)
|
Name of Person Filing
Lord, Abbett & Co. LLC
|
|
|
|
|
(b)
|
Address of Principal
Business Office or, if none, Residence
90 Hudson Street
Jersey City, NJ 07302.
|
|
|
|
|
(c)
|
Citizenship
See No. 4 on page 2.
|
|
|
|
|
(d)
|
Title of Class of Securities
See cover page.
|
|
|
|
|
(e)
|
CUSIP Number
See cover page.
|
|
|
|
|
Item 3.
|
If this statement is filed
pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person
filing is a:
|
|
|
|
(a)
|
o
|
Broker or dealer
registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
|
|
(b)
|
o
|
Bank as defined in section
3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
(c)
|
o
|
Insurance company as
defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
(d)
|
o
|
Investment company
registered under section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8).
|
|
|
|
|
|
(e)
|
x
|
An investment adviser in
accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
(f)
|
o
|
An employee benefit plan
or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
(g)
|
o
|
A parent holding company
or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
(h)
|
o
|
A savings association as
defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813);
|
|
|
|
|
|
(i)
|
o
|
A church plan that is
excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
|
|
|
|
(j)
|
o
|
A non-U.S. institution in
accordance with § 240.13d1(b)(1)(ii)(J);
|
|
|
|
|
|
(k)
|
o
|
Group, in accordance with
§ 240.13d1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance
with § 240.13d1(b)(1)(ii)(J), please specify the type of
institution:____________________________
|
3
|
|
|
|
Item 4.
|
Ownership
|
|
|
Provide the following
information regarding the aggregate number and percentage of the class of
securities of the issuer identified in Item 1.
|
|
|
|
|
|
(a)
|
Amount beneficially owned:
See No. 9 on page 2.
|
|
|
|
|
(b)
|
Percent of class:
See No. 11 on page 2.
|
|
|
|
|
(c)
|
Number of shares as to
which the person has:
|
|
|
|
|
|
|
|
|
(i)
|
Sole power to vote or to
direct the vote
See No. 5 on page 2.
|
|
|
|
|
|
|
(ii)
|
Shared power to vote or to
direct the vote
See No. 6 on page 2.
|
|
|
|
|
|
|
(iii)
|
Sole power to dispose or
to direct the disposition of
See No. 7 on page 2.
|
|
|
|
|
|
|
(iv)
|
Shared power to dispose or
to direct the disposition of
See No. 8 on page 2.
|
|
|
|
|
|
Item 5.
|
Ownership
of Five Percent or Less of a Class
|
|
If this statement is being
filed to report the fact that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five percent of the class of
securities, check the following
þ
.
|
|
Item 6.
|
Ownership
of More than Five Percent on Behalf of Another Person
|
|
|
Securities reported on
this Schedule 13G as being beneficially owned by Lord, Abbett & Co. LLC
are held on behalf on investment advisory clients, which may include
investment companies registered under the Investment Company Act, employee
benefit plans, pension funds or other institutional clients.
|
|
|
Not applicable.
|
|
Item 7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being
Reported on by the Parent Holding Company or Control Person
|
|
Not applicable.
|
|
Item 8.
|
Identification
and Classification of Members of the Group
|
|
Not applicable.
|
|
Item 9.
|
Notice of
Dissolution of Group
|
|
|
Not applicable.
|
4
|
|
Item 10.
|
Certification
|
|
|
By signing below I certify
that, to the best of my knowledge and belief, the securities referred to
above were acquired and are held in the ordinary course of business and were
not acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any
transaction having that purpose or effect.
|
Signature
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set
forth in this statement is true, complete and correct.
|
|
|
October
10, 2012
|
|
|
|
Date
|
|
|
|
/s/
Lawrence H. Kaplan
|
|
|
|
Signature
|
|
|
|
Lawrence
H. Kaplan/Member
|
|
|
|
Name/Title
|
5
Pharmacutical (NYSE:PRX)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmacutical (NYSE:PRX)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Pharmaceutical Companies (New York Stock Exchange): 0 recent articles
More News Articles